Chromadex Corp (OQ:CDXC)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 10900 Wilshire Blvd Ste 600
LOS ANGELES CA 90024-6534
Tel: 1-949-6009727
IR: See website
Key People
Frank L. Jaksch
Executive Chairman of the Board
Robert N. Fried
President, Chief Executive Officer, Chief Operating Officer, Chief Strategy Officer, Director
Kevin M. Farr
Chief Financial Officer
Matthew A. Roberts
Senior Vice President - Innovation, Chief Scientific Officer
Megan Jordan
Chief Communications Officer, Senior Vice President - Global Marketing
Mark Friedman
General Counsel, Corporate Secretary
Business Overview
Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.
Financial Overview
For the fiscal year ended 31 December 2019, Chromadex Corp revenues increased 47% to $46.3M. Net loss decreased 4% to $32.1M. Revenues reflect Consumer Products Segments increase of 96% to $36.1M. Lower net loss reflects Consumer Products Segments income totaling $483K vs. loss of $7.7M, Ingredients Segments income increase of 63% to $2.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.61 to -$0.56.
Employees: 110 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $169.80M as of Dec 31, 2019
Annual revenue (TTM): $46.29M as of Dec 31, 2019
EBITDA (TTM): -$30.29M as of Dec 31, 2019
Net annual income (TTM): -$32.15M as of Dec 31, 2019
Free cash flow (TTM): -$21.19M as of Dec 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 59,787,897 as of Mar 3, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization